儿童社区获得性肺炎短程与标准程门诊抗生素治疗:SCOUT-CAP随机临床试验
该随机双盲安慰剂对照试验纳入380例6至71月龄非重症社区获得性肺炎且早期临床改善的儿童,比较5天短程与10天标准程抗生素策略。短程策略在RADAR复合终点上更优(概率69%,95%CI 63-75),临床反应和不良反应相似,且总抗生素耐药基因和β-内酰胺酶耐药基因显著降低。
要点
- 早期临床改善的CAP患儿,5天抗生素策略在RADAR终点上优于10天策略。
- 短程与标准程的临床反应和抗生素相关不良反应无差异。
- 短程策略可降低口咽菌群总耐药基因和β-内酰胺酶耐药基因数量。
核心结论
- 对于初始治疗有反应的CAP患儿,5天抗生素策略优于10天策略。
- 短程策略临床反应和抗生素相关不良反应与标准程相似,但减少抗生素暴露和耐药。
研究设计与样本
- 随机双盲安慰剂对照临床试验,在美国8个城市的门诊、急诊或紧急护理机构开展。
- 纳入380例6至71月龄非重症CAP且早期临床改善的儿童,随机1:1接受5天安慰剂或5天同种抗生素。
- 主要终点为调整抗生素疗程风险的治疗结束反应(RADAR),部分儿童检测口咽菌群耐药基因。
主要发现
- 两种策略在DOOR及其各组分上无差异,两组临床反应不足者均少于10%。
- 短程策略相比标准程策略获得更理想RADAR结局的概率为69%(95%CI 63-75)。
关键数值与推荐
- 短程策略:在最初处方治疗第6天起接受5天匹配安慰剂。
- 标准程策略:在最初处方治疗第6天起接受5天同种抗生素。
- 主要终点RADAR按临床反应、症状缓解和抗生素相关不良反应的序贯结局排序,并优先 shorter 抗生素天数。
临床怎么用
- 对初始治疗有早期临床改善的门诊CAP患儿,可考虑5天抗生素短程策略。
- 短程策略在不增加临床失败或不良反应的同时减少抗生素暴露和耐药选择。
局限性
- 研究仅纳入非重症且早期临床改善的6至71月龄儿童,结论不能外推至其他人群。
- 耐药基因分析仅纳入171例儿童,为部分 subset。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Childhood community-acquired pneumonia (CAP) is usually treated with 10 days of antibiotics. Shorter courses may be effective with fewer adverse effects and decreased potential for antibiotic resistance. OBJECTIVE: To compare a short (5-day) vs standard (10-day) antibiotic treatment strategy for CAP in young children. DESIGN, SETTING, AND PARTICIPANTS: Randomized double-blind placebo-controlled clinical trial in outpatient clinic, urgent care, or emergency settings in 8 US cities. A total of 380 healthy children aged 6 to 71 months with nonsevere CAP demonstrating early clinical improvement were enrolled from December 2, 2016, to December 16, 2019. Data were analyzed from January to September 2020. INTERVENTION: On day 6 of their originally prescribed therapy, participants were randomized 1:1 to receive 5 days of matching placebo or 5 additional days of the same antibiotic. MAIN OUTCOMES AND MEASURES: The primary end point was the end-of-treatment response adjusted for duration of antibiotic risk (RADAR), a composite end point that ranks each child's clinical response, resolution of symptoms, and antibiotic-associated adverse effects in an ordinal desirability of outcome ranking (DOOR). Within each DOOR rank, participants were further ranked by the number of antibiotic days, assuming that shorter antibiotic durations were more desirable. Using RADAR, the probability of a more desirable outcome was estimated for the short- vs standard-course strategy. In a subset of children, throat swabs were collected between study days 19 and 25 to quantify antibiotic resistance genes in oropharyngeal flora. RESULTS: A total of 380 children (189 randomized to short course and 191 randomized to standard course) made up the study population. The mean (SD) age was 35.7 (17.2) months, and 194 participants (51%) were male. Of the included children, 8 were Asian, 99 were Black or African American, 234 were White, 32 were multiracial, and 7 were of unknown or unreported race; 33 were Hispanic or Latino, 344 were not Hispanic or Latino, and 3 were of unknown or unreported ethnicity. There were no differences between strategies in the DOOR or its individual components. Fewer than 10% of children in either strategy had an inadequate clinical response. The short-course strategy had a 69% (95% CI, 63-75) probability of a more desirable RADAR outcome compared with the standard-course strategy. A total of 171 children were included in the resistome analysis. The median (range) number of antibiotic resistance genes per prokaryotic cell (RGPC) was significantly lower in the short-course strategy compared with the standard-course strategy for total RGPC (1.17 [0.35-2.43] vs 1.33 [0.46-11.08]; P = .01) and β-lactamase RGPC (0.55 [0.18-1.24] vs 0.60 [0.21-2.45]; P = .03). CONCLUSIONS AND RELEVANCE: In this study, among children responding to initial treatment for outpatient CAP, a 5-day antibiotic strategy was superior to a 10-day strategy. The shortened approach resulted in similar clinical response and antibiotic-associated adverse effects, while reducing antibiotic exposure and resistance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02891915.
引用
- Williams DJ, Creech CB, Walter EB, et al. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial. JAMA Pediatr. 2022. PMID: 35040920. doi:10.1001/jamapediatrics.2021.5547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。